Search

Your search keyword '"Chanteloup E"' showing total 5 results
Start Over Author "Chanteloup E" Database OpenAIRE
5 results on '"Chanteloup E"'

1. Efficacy of vedolizumab in perianal Crohn's disease: the BioLAP multi-centre observational study

Author

Biron, C., Seksik, P., Nachury, M., Nancey, S., Bouhnik, Y., Serrero, M., Armengol-Debeir, L., Buisson, Anthony, Minh, M. -L. Tran, Zallot, C., Fumery, Mathurin, Bouguen, G., Abitbol, V., Viennot, S., Chanteloup, E., Rajca, S., Dib, N., Peyrin-Biroulet, L., Vuitton, L., Service de Gastro-Entérologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Claude Huriez [Lille], CHU Lille, Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille], Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), CHU Clermont-Ferrand, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Gastro entérologie [Hôpital Paris Saint-Joseph], Hôpital Paris Saint-Joseph, Hôpital Louis Mourier - AP-HP [Colombes], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), and European Crohn’s and Colitis Organisation

Subjects
[SDV]Life Sciences [q-bio], [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019
Full Text
View/download PDF

2. Efficacy of ustekinumab in perianal Crohn's disease: the BioLAP multi-centre observational study

Author

Biron, C., Seksik, P., Nachury, M., Bouhnik, Y., Amiot, A., Viennot, S., Serrero, M., Fumery, Mathurin, Allez, M., Siproudhis, L., Buisson, A., Chambrun, G. Pineton, Abitbol, V., Nancey, S., Caillo, L., Plastaras, L., Armengol-Debeir, L., Chanteloup, E., Simon, M., Dib, N., Rajca, S., Amil, M., Peyrin-Biroulet, L., Vuitton, L., Service de Gastro-Entérologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Claude Huriez [Lille], CHU Lille, Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de gastro-entérologie [Henri Mondor AP-HP, Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Gastro-entérologie [CHU Hôpital Nord - Marseille], Hôpital Nord [CHU - APHM]-Assistance publique Hôpitaux de Marseille (APHM), Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), CHU Clermont-Ferrand, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Hôpital pasteur [Colmar], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Gastro entérologie [Hôpital Paris Saint-Joseph], Hôpital Paris Saint-Joseph, Institut mutualiste Monsouris (IMM), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital Louis Mourier - AP-HP [Colombes], Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), and European Crohn’s and Colitis Organisation

Subjects
[SDV]Life Sciences [q-bio], [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019
Full Text
View/download PDF

3. Predictors of immunogenicity to anti-TNF therapy in IBD: results of the ABIRISK study

Author

Allez, Matthieu, Hässler, Signe, Carbonnel, Franck, Chowers, Yehuda, Bouhnik, Yoram, Maria, N., Cadiot, Guillaume, Trang, C., Seksik, Philippe, Buisson, A., Chanteloup, E., Nancey, Stéphane, Louis, E., Hebuteme, X., Simon, M., Szely, Natacha, Gleizes, Aude, Hacein-Bey Abina, Salima, Birchler, Mary, Hincelin Mery, Agnès, Deisenhammer, Florian, Pallardy, Marc, Broët, Philippe, and Hässler, Signe

Subjects
[SDV.IMM] Life Sciences [q-bio]/Immunology, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, adalimumab, Anti-drug antibodies, infliximab, Anti-drug antibodies infliximab adalimumab, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
Abstract

Introduction: ABIRISK is a multicenter, prospective, non-interventional study based on cohorts of patients with IBD, multiple sclerosis, rheumatoid arthritis. Patients are included at the start of biopharmaceuticals. Biological samples are collected, to find biomarkers predictive of efficacy and immunization. We herein report the results observed in the IBD cohort of patients treated with anti TNFs. Aims and Methods: Patients treated with adalimumab (ADL) or infliximab (IFX) as a first-line therapy for active IBD were eligible. Anti-drug antibodies (ADAb) were measured a chemoluminescence drug tolerant capture ELISA assay at W0, W6, W12 and W52. Immunogenicity was defined as ADAb within the first 12 months of anti TNF treatment. Clinical activity was assessed at W6, W12, W52 and at withdrawal if the drug was discontinued. Surgical and medical history, including previous medications were reported at inclusion, while adverse events, including those related to ADAb, and concomitant medications were reported at any time points. Clinical remission was defined as a HBI≤3 in CD patients and a Mayo subscore≤4 in UC patients. Patients who discontinued ADL or IFX or who were lost to follow-up were considered as treatment failures. Results: 204 eligible patients were recruited from 17 centers (France, Belgium and Israel). 197 were included (7 screen failures) of whom 184 patients could be assessed (mean age was 36.9 (SD:13.7), 48.4% were women). There were 148 patients with CD and 36 with UC. 86 patients were treated with IFX (n=86, REM or CT-P13) and 98 with ADL. Median disease duration was 3.69 (IQR: 10.37) years. In CD, median Harvey-Bradshaw index was 6, 27 had a penetrating phenotype (B3) (IFX, n=17; ADL, n=10) and 23 had perianal fistulas (IFX, n=18 ADL, n=6). In UC, median Mayo subscore was 6. 19.6% had extra-intestinal manifestations. Concomitant immunosuppressants were prescribed in 68% and 40% of patients treated with IFX and ADA respectively. 82% and 35 % of patients treated with IFX and ADL received corticosteroids, respectively. At one year, 95 patients (51.6%) were in clinical remission, including 73 (40%) without optimization of anti-TNF therapy. ADAb were detected in 51 patients (27.7%). The immunogenicity rate for ADL and IFX was 38.8% and 15.1%, respectively. Mean time to onset of ADAb was 2.5 months, and ADAb persisted over time in 72%. Drug levels at 6 weeks of therapy were significantly lower in patients who developed ADAb. Immunogenicity was associated with non-remission at one year (58.6% in patients with ADAb vs 35.7% in patients without ADAb, p=0.008). In multivariate cox regression analysis of time to ADAb development, immunogenicity was associated with concomitant immunosuppressant (HR: 0.39 [95% CI 0.2-0.75]), anti-TNF levels at 6 weeks of therapy (HR: 0.86 [95% CI 0.8-0.91]), antibiotics usage during the study (HR: 0.3 [95% CI 0.14-0.65]) and vaccine in the year before start of anti-TNF therapy (HR: 3.1 [95% CI 1.5-6.3]). Conclusion: In IBD patients, immunogenicity towards anti TNFs is associated with a lower remission rate and lower drug levels. Concomitant immunosuppressants and antibiotics are associated with a lower risk of immunogenicity while vaccine received before the start of anti TNF are associated with an increased risk of immunogenicity.

Published
2018

4. A negative screening does not eliminate tuberculosis risk under anti-TNF treatment in inflammatory bowel disease: a descriptive study

Author

Abitbol, Y., Laharie, D., Cosnes, J., Allez, M., Nancey, S., Amiot, Audrey, Aubourg, A., Fumery, Mathurin, Altwegg, R., Michetti, P., Chanteloup, E., Seksik, P., Abitbol, V., Baudry, C., Flamant, M., Bouguen, G., Stefanescu, C., Bourrier, A., Bommelaer, G., Dib, N., Bigard, M. A., Viennot, S., Hébuterne, X., Gornet, J. M., Marteau, P., Bouhnik, Y., Nahon, S, Service de Gastroentérologie et nutrition [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service d’hépatogastroenterologie, CHU Amiens-Picardie, Département de gastroentérologie, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Foie, métabolismes et cancer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Service de gastroentérologie, MICI et assistance nutritive, pôle des maladies de l’appareil digestif, Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Nice (CHU de Nice), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), AP-HP, Hôpital Lariboisière, Hôpital Lariboisière-Fernand-Widal [APHP], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Nice (CHU Nice), and Université Nice Sophia Antipolis (1965 - 2019) (UNS)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience; Meeting abstract Sa1949

Published
2016
Full Text
View/download PDF

5. De la réparation à la restauration : la revégétalisation de pistes de ski à l'Alpe d'Huez

Author

Céline Granjou, Gaucherand, S., Chanteloup, E., and Irstea Publications, Migration

Subjects
[SDE] Environmental Sciences, Physical geography, Alps, ecological restoration, lcsh:Geography. Anthropology. Recreation, ski resort, GB3-5030, lcsh:G, restauration écologique, Geography. Anthropology. Recreation, revégétalisation, revegetation, lcsh:GB3-5030, station de ski, lcsh:Physical geography, Alpes
Abstract

The study adopts an empirical sociological approach to analyse how the objectives behind the revegetation of ski trails and runs in the French alpine resort of Alpe d’Huez have evolved since the 1970s. A revegetation programme was first introduced to repair the scars left by the works conducted to equip the resort with infrastructures, and then, over time, it became a more complex restoration project. At first, revegetation techniques were developed to fight soil erosion, but soon also became associated with the idea of “turning the mountain green again”. Now, 40 years later, revegetation is aimed at restoring both a natural ecosystem and a cultural landscape. The ski resort’s managers, local farmers, technicians, and those conducting research in the area share a common desire to promote autochthony, which in some cases runs the risk of reproducing folklore. Far from adopting an overriding ethical perspective, the study suggests that the area’s physical characteristics, specific history and configuration of local actors have shaped and continue to shape both the manner in which ecological restoration is implemented, through political choices and technical decisions, and the debates it gives rise to. The study concludes by examining the specificity of the findings for Alpe d’Huez and discussing their validity for other alpine ski resorts.A partir d’une approche sociologique empirique, ce texte propose une analyse de la mise en œuvre de la revégétalisation sur la station de l’Alpe d’Huez depuis les années 1970. Il montre comment la revégétalisation est passée d’un objectif de réparation des cicatrices provoquées par les aménagements à une entreprise plus complexe de restauration. S’il s’agissait au départ de répondre à un objectif technique de lutte contre l’érosion, la revégétalisation a pris rapidement une tournure paysagère (reverdissement) ; elle a ensuite été pensée dans une perspective de restauration des écosystèmes ainsi que de restauration d’un paysage culturel « typique ». Aujourd’hui, gestionnaires de la station, techniciens, agriculteurs et chercheurs impliqués partagent un désir d’autochtonie qui touche dans certains cas à la foklorisation. Loin d’une perspective éthique surplombante, cette étude suggère ainsi comment les caractéristiques physiques du territoire, son histoire et la configuration des acteurs locaux informent largement les arbitrages et les choix techniques qui président à la restauration écologique, ainsi que les débats qui l’entourent. En conclusion, nous discutons de la spécificité de nos résultats et de leur validité pour d’autres stations alpines.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results